Melatonin appears to target both pain and sleep, making it particularly useful
For the nearly half of humanity living with chronic musculoskeletal pain, the search for relief has long meant navigating medications that carry their own burdens — dependence, side effects, diminishing returns. Researchers at the University of Sydney have now found that melatonin, a humble supplement already resting in many medicine cabinets, can reduce chronic pain at levels comparable to opioids and NSAIDs, while also mending the sleep that pain so often steals. The finding, drawn from 23 randomized trials across five countries, does not promise a cure, but it quietly expands the map of what is possible — and at a cost of less than a cup of coffee.
- Chronic musculoskeletal pain touches 47% of people globally, and the medications most commonly used to treat it carry serious risks of dependence, side effects, and long-term harm.
- A University of Sydney analysis of 2,028 adults across 23 trials found melatonin reduced pain by roughly nine points on a 100-point scale — a margin that matches conventional painkillers like opioids, NSAIDs, and paracetamol.
- Beyond pain relief, melatonin broke the vicious cycle many patients know well: by improving sleep quality simultaneously, it addressed the second force that makes chronic pain so relentless.
- Side effects were mild — occasional nausea, dizziness, or headaches — occurring at rates no higher than placebo, with no dependence risk and no serious adverse events reported across the trials.
- Researchers are urging caution rather than a wholesale switch, framing melatonin as an adjunct to existing treatment plans rather than a replacement, and calling for larger studies to solidify the evidence.
Researchers at the University of Sydney have discovered that melatonin — widely known as a sleep aid — can reduce chronic musculoskeletal pain at levels comparable to opioids, NSAIDs, and paracetamol. Published in the journal PAIN, the finding arrives as doctors and patients increasingly seek alternatives to medications that carry real risks of dependence and serious side effects.
The study pooled data from 2,028 adults across 23 randomized controlled trials conducted in five countries. Participants lived with conditions ranging from low back pain and osteoarthritis to fibromyalgia, and some were recovering from joint replacements or spinal surgeries. On average, melatonin reduced pain by about nine points on a 0-to-100 scale — a reduction that matched conventional pain medications, approaching ten points in the most rigorous trials.
The scale of the problem makes the finding significant. Musculoskeletal pain affects roughly 47% of people globally. Lead author Kangchao Wu highlighted melatonin's practical appeal: it is already widely available, costs less than $1.50 per tablet in Australia, and carries a well-established safety profile. Crucially, the supplement also improved sleep quality in participants — addressing the vicious cycle in which poor sleep and chronic pain each worsen the other, something conventional pain medications rarely accomplish.
Doses across the trials ranged from 3 to 10 mg for chronic pain and 1 to 10 mg for postoperative pain, with most participants taking melatonin at or near bedtime. No clear dose-response relationship emerged, so no single optimal dose can yet be recommended. Side effects — nausea, dizziness, headaches — were mild and occurred at rates similar to placebo, with no dependence risk and no serious adverse events reported.
The researchers are careful to position melatonin as an addition to pain management rather than a replacement. Wu advised patients to consult their doctor before starting it, especially if they take other medications. As concerns about long-term opioid use continue to grow, the findings point toward a tool that is already affordable and accessible — one that may quietly reshape how chronic musculoskeletal pain is approached, even as larger studies work to deepen the evidence.
Researchers at the University of Sydney have found that melatonin, a supplement most people know as a sleep aid, can reduce chronic musculoskeletal pain at levels comparable to opioids, NSAIDs, and paracetamol. The discovery, published in the journal PAIN, arrives at a moment when doctors and patients alike are searching for alternatives to medications that carry real risks of dependence and serious side effects.
The study pooled data from 2,028 adults across 23 randomized controlled trials conducted in the United States, Russia, Brazil, Egypt, and China. Participants had conditions ranging from low back pain and osteoarthritis to fibromyalgia, and some were recovering from surgeries like joint replacements and spinal procedures. On average, melatonin reduced pain by about nine points on a 0-to-100 scale—a reduction that matched the effect size of conventional pain medications. In the most rigorous trials, the reduction approached ten points.
What makes this finding particularly relevant is the scale of the problem it addresses. Musculoskeletal pain affects roughly 47 percent of people globally, making it one of the most common sources of chronic suffering. Kangchao Wu, the lead author and a PhD student at the university's Musculoskeletal Research Hub, emphasized the practical appeal: melatonin is already in many people's homes, costs less than $1.50 per tablet in Australia, and carries a well-established safety profile. "What's exciting is that melatonin may also help manage chronic pain, opening the door to reducing reliance on medications that come with more risks," Wu said.
The research also uncovered a secondary benefit that may prove equally important. Melatonin improved sleep quality in study participants, addressing a problem that often compounds chronic pain. For many people living with persistent musculoskeletal pain, poor sleep and pain form a vicious cycle—each worsens the other. By targeting both problems simultaneously, melatonin offers something conventional pain medications often cannot.
Doses in the trials varied depending on the condition and context. For chronic musculoskeletal pain, typical doses ranged from 3 to 10 milligrams daily, with 3 mg being most common. For postoperative pain, doses ranged from 1 to 10 mg, with 5 to 6 mg most frequently used. Most participants took melatonin at bedtime or within an hour before sleep. Notably, the researchers found no clear dose-response relationship, meaning the current evidence does not support recommending a single optimal dose.
The safety profile was reassuring. The most commonly reported side effects were nausea, dizziness, and headaches—all mild and occurring at rates similar to placebo. No serious adverse events were reported, and melatonin shows no evidence of dependence. The supplement is generally considered safe for short-term use of less than three months. In Australia, melatonin's regulatory status complicates access: most products require a prescription, though pharmacists can dispense low-dose melatonin (2 mg or less) without one for short-term insomnia treatment in adults over 55.
The researchers are careful to frame melatonin not as a replacement for existing pain medications but as a potential addition to a broader pain management strategy. Wu stressed that patients should consult their doctor before starting melatonin, particularly if they take other medications or have underlying health conditions. "Our advice isn't for melatonin to replace every pain medication," he said. "Instead, after consultation with a doctor, it may be used as an adjunct to existing treatments, particularly for people who also experience sleep problems."
As concerns about long-term opioid use continue to mount, and as patients and clinicians seek safer alternatives, this research points toward a tool that is already widely available and affordable. The findings are strong enough to support cautious clinical uptake, though researchers acknowledge that larger studies will further strengthen the evidence base. What remains to be seen is whether this shift—from melatonin as a sleep supplement to melatonin as part of pain management—will reshape how doctors and patients approach chronic musculoskeletal pain.
Notable Quotes
Melatonin is already in people's homes, it's inexpensive, and we know it's safe. What's exciting is that melatonin may also help manage chronic pain, opening the door to reducing reliance on medications that come with more risks.— Kangchao Wu, lead author and PhD student, University of Sydney
Our advice isn't for melatonin to replace every pain medication. Instead, after consultation with a doctor, it may be used as an adjunct to existing treatments, particularly for people who also experience sleep problems.— Kangchao Wu
The Hearth Conversation Another angle on the story
Why does melatonin work for pain when it's designed to regulate sleep?
The research doesn't fully explain the mechanism, but the connection between sleep and pain is real and bidirectional. Poor sleep amplifies pain perception, and pain disrupts sleep. Melatonin seems to interrupt that cycle by improving sleep quality, which then allows the body to manage pain better. It may also have direct anti-inflammatory effects, though that's still being studied.
If it's this effective and safe, why isn't it already standard treatment?
Partly because it's not a new drug—there's no patent incentive for pharmaceutical companies to fund large trials. Melatonin is cheap and available, which is good for patients but doesn't drive the research machine. Also, regulatory frameworks vary by country. In Australia, for instance, you need a prescription for most melatonin products, which creates a barrier even if doctors wanted to recommend it.
The study says it works as well as opioids. Doesn't that seem too good to be true?
The pain reduction is comparable in magnitude—about nine points on a 100-point scale—but that doesn't mean it's a one-to-one replacement. Opioids work differently and may be necessary for acute, severe pain. What's valuable here is that melatonin offers meaningful relief for chronic pain without the addiction risk or serious side effects. It's not a miracle; it's a safer option for a specific problem.
What about the people who don't sleep well even with melatonin?
That's a real limitation. The research shows melatonin helps many people, but not everyone. Some people are simply non-responders. That's why the researchers emphasize it should be part of a broader pain management plan, not a standalone solution. It works best for people where sleep disruption is a significant part of their pain problem.
How quickly could this change clinical practice?
That depends on doctors' willingness to prescribe it and regulatory changes. In countries where melatonin is available over-the-counter, adoption could be faster. In Australia, the prescription requirement slows things down. But the evidence is strong enough that informed doctors can already discuss it with patients as an option worth trying, especially for those struggling with both pain and sleep.